Adaptive Biotechnologies (ADPT) Receivables (2018 - 2026)

Adaptive Biotechnologies has disclosed Receivables across 9 years of filings, most recently posting $51.3 million for Q2 2026.

• In Q2 2026, Receivables rose 12.57% year-over-year to $51.3 million; the TTM figure through Jun 2026 stood at $51.3 million (up 12.57% YoY), while the FY2025 annual figure was $51.9 million, up 20.53% from the prior year.
• Receivables came in at $51.3 million for Q2 2026 at Adaptive Biotechnologies, up from $49.9 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $51.9 million in Q4 2025 to a low of $23.6 million in Q1 2022.
• Average Receivables over 5 years is $39.3 million, with a median of $41.5 million recorded in 2022.
• Year-over-year, Receivables surged 117.22% in 2022 and retreated 4.62% in 2023.
• Over 5 years, Receivables stood at $40.9 million in 2022, then dropped by 4.62% to $39.0 million in 2023, then rose by 10.42% to $43.0 million in 2024, then advanced by 20.53% to $51.9 million in 2025, then retreated by 1.06% to $51.3 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $51.3 million in Q2 2026, $49.9 million in Q1 2026, and $51.9 million in Q4 2025.